July 8, 2021 7:29am
Pre-open indications: 4 Sells: CRSP, EDIT, CLLS, SGMO; 1 Maintain SELL: BSTG
My version of the morning’s “indications” is about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session
Subscription is coming in July, it’s not conscription but, an offer to join our collective of like-minded investors!
Dow futures are DOWN -1.35% (-467 points), S&P futures are DOWN -1.28% (-56 point) and NASDAQ futures are -1.23% (-183 points)
Pre-open futures are looking grim over economic concerns Thursday morning,
European stocks were lower amid a more cautious turn in global sentiment,
Asia-Pacific stocks declined as Chinese stocks in Hong Kong came under pressure after regulatory fears resurfaced.
Data Docket: latest jobless claims figures
Henry’omics:
Futures contracts tied to the major U.S. stock indexes fell in early morning trading Thursday.
The losses came as Japan declared a state of emergency in Tokyo for the upcoming Olympics and as countries deal with a rebound in cases because of Covid variants. <CNBC>
It's a good day to turn-off the markets and sectors and wait to be disappointed later than through-out the session.
Wednesday’s evening’s recap: “fear while staring down the cell and gene therapy sector abyss” …https://www.regmedinvestors.com/articles/11988
- The Nasdaq closed UP +1.42 points (+0.01%);
- The IBB closed down -0.88% and XBI closed down -1.68%;
- Sector volume was LOW with 3 of the 8-upside having higher than the 3-month average volume with LOW volume of 4 of 25-downside having higher than the 3-month average volume;
- The CBOE Volatility Index (VVIX: INDEX) was down -0.24 points or -1.46% at 16.20;
- Wednesday’s percentage (%) of the 8-upside were +0.02% (SAGE) to +2.87% (VCEL) while the 25-downside ranges from -0.19% (AXGN) to -15.33% (BSTG);
Q3/21: 1 positive and 3 negative close
Q2/21:
- June: 15 positive and 8 negative closes
- May: 8 positive, 12 negative closes and 1 holiday
- April: 11 negative and 10 positive closes
Q1/21:
- March: 10 positive, 12 negative and 1 neutral closes
- February: 9 positive, 10 negative closes and 1 holiday
- January: 10 positive, 9 negative closes and 1 holiday
Companies in my headlights – It’s your decision; I provide an idea and context:
The Biostage (BSTG) - Maintaining Sell – Could the share price stay up if it wasn’t “pumped”?
Biostage (BSTG) closed down -$0.23 to $1.27 with 15,903 shares traded after Tuesday’s +$0.15 to $1.50 with 5,702 shares traded, Friday’s -$0.00 with 1,974 shares traded and last Thursday’s +$0.095 to $1.35 with 408 shares traded.
Question#1: WHAT role is DST Capital “playing” in these on-going “volume-pumping” pricing “moves” – to exercise the remaining outstanding warrants to add even more unregistered shares to the “outstanding”?
Question#2: WHO and WHAT has facilitated <” made it easy or easier to get where they are”> most of the issues with BSTG?
MINORITY PUBLIC shareholders are waiting for the specific time, watching and weighing responses to MAINTAIN their RIGHTS.
The morning’s indications:
SELL:
CRISPR Therapeutics (CRSP) closed down -$7.78 to $148.10 after Friday’s -$0.76 to $165.88, Thursday’s -$5.25 to $156.64 and last Wednesday’s +$11.40 to $161.89 with a negative -$5.98 or -4.20% pre-market indication.
Editas Medicine (EDIT) closed down -$6.76 to $48.14 after Friday’s -$1.62 to $54.90, Thursday’s -$0.12 to $56.52 and Wednesday’s +$10.54 to $56.64 with a positive -$2.00 or -4.38% pre-market indication.
Cellectis SA (CLLS) closed down -$0.52 to $14.34 after Tuesday’s $14.86 with a negative -$0.44 or -3.07% aftermarket indication.
Sangamo Therapeutics (SGMO) closed down -$0.37 to $10.88 after Tuesday’s -$0.46 to $11.25 and Friday’s -$0.30 to $11.71 with a negative -$0.29 or -2.67% pre-market indication.
Ultragenyx (RARE) closed down -$1.79 to $89.63 after Tuesday’s $91.42 and has a negative -$1.98 or -2.21% aftermarket indication.
The BOTTOM LINE: It takes courage to not being discouraged by this sector …
In my role as a research analyst and journalist is a balancing “act”, WHAT CHANGES; many times, I scratch my head over how to cover volatile cell and gene therapy equities – it’s the INDICATIONS that focus my “leanings”.
I also continue to MAINTAIN, this is a confused sector as sentiment rages and fades, momentum is usurped, fundamentals are being ignored.
My focus has always been “indication and warning analysis” … my advice, trim and skim any new highs if one can!” I also see a number of lows that could be in the “pick-up” stock game.
My motto, never leave an investor uninformed about what I know!
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
